Journal of hematology and oncology, 2019-04, Vol.12 (1), p.45-45, Article 45
2019
Details
- Autor(en) / Beteiligte
- Titel
- Emerging therapies for non-small cell lung cancer
- Ist Teil von
- Journal of hematology and oncology, 2019-04, Vol.12 (1), p.45-45, Article 45
- Ort / Verlag
- England: BioMed Central Ltd
- Erscheinungsjahr
- 2019
- Link zum Volltext
- Quelle
- EZB Electronic Journals Library
- Beschreibungen/Notizen
- Recent advances in the field of novel anticancer agents prolong patients' survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing rapid development. Although increasing novel anticancer agents were innovated, how to translate and optimize these novel agents into clinical practice remains to be explored. Besides, toxicities and availability of these drugs in specific regions should also be considered during clinical determination. Herein, we summarize emerging agents including tyrosine kinase inhibitors, checkpoint inhibitors, and other potential immunotherapy such as chimeric antigen receptor T cell for non-small cell lung cancer attempting to provide insights and perspectives of the future in anticancer treatment.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1756-8722eISSN: 1756-8722DOI: 10.1186/s13045-019-0731-8Titel-ID: cdi_doaj_primary_oai_doaj_org_article_d3cbcea08afa46f0863babebc2c4db61
- Format
- –
- Schlagworte
- Antibodies, Antigens, Antineoplastic agents, Antitumor agents, Bevacizumab, Bispecific antibodies, Cancer therapies, Cancer treatment, CAR-T, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - pathology, Care and treatment, Checkpoint inhibitors, Chemotherapy, Chimeric antigen receptors, Clinical trials, Complications and side effects, Crizotinib, Development and progression, Dosage and administration, Drug dosages, Drug therapy, Epidermal growth factor, FDA approval, Humans, Immune checkpoint, Immunotherapy, Immunotherapy - methods, Kinase inhibitors, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - pathology, Lymphocytes T, Metastasis, Monoclonal antibodies, Mutation, Non-small cell lung cancer, Non-small cell lung carcinoma, Patients, Phenols (Class of compounds), Protein-tyrosine kinase, Review, Small cell lung cancer, T cells, Toxicity, Tyrosine, Tyrosine kinase inhibitors